J Med Virol . Administration of intravenous immunoglobulin in the treatment of COVID-19: a review of available evidence

[tetano]

J Med Virol


. 2020 Dec 12.
doi: 10.1002/jmv.26727. Online ahead of print.
Administration of intravenous immunoglobulin in the treatment of COVID-19: a review of available evidence


Parisa Moradimajd ¹ , Hamidreza Samaee ² , Shahnam Sedigh-Maroufi ¹ , Masoumeh Kourosh-Aami ³ , Monireh Mohsenzadagan ⁴



Affiliations

• PMID: 33314173
• DOI: 10.1002/jmv.26727

Abstract

Since December 31, 2019, unknown causes of pneumonia have been reported in Wuhan, China. This special pneumonia associated with a novel coronavirus was named 2019-nCoV by the World Health Organization (WHO) in January 2020. From the beginning of this infectious disease, clinicians and researchers have been endeavoring to discover an effective and suitable treatment for affected patients. To date, there is no definitive and specific treatments for coronavirus disease -19 (COVID-19) infection while drugs introduced are still in the clinical trial phase. Intravenous immune globulin (IVIG) is a biological product prepared from the serum and optional treatment for patients with antibody deficiencies. In many countries, much attention has been paid to the use of IVIG in the treatment of patients with COVID-19. Due to the therapeutic importance of IVIG in virus infections, in the current study, we reviewed the possible effect of IVIG in viral infections and potential evidence of IVIG therapy in patients with COVID-19 virus. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Coronavirus; IVIG Therapy; Intravenous Immune Globulin; Viral Infection.